Transkaryotic Therapies Incorporated RKT Company Profile

19:01 EDT 21st September 2017 | BioPortfolio

Founded in 1988, Transkaryotic Therapies, Inc. (TKT) is a leading biopharmaceutical company in the production and delivery of protein therapies. TKT develops, and intends to commercialize, protein products for rare and common diseases. Through its three development platforms Niche Protein® products, Gene-Activated® proteins, and Gene Therapy, TKT currently has products in clinical development for the treatment of Fabry disease, anemia, Hunter syndrome, hemophilia A. The breadth of TKT's pipeline is a result of the company's strong scientific base, which integrates cellular and molecular biology and protein chemistry to develop biologics.


195 Albany Street
United States of America


Phone: 617 349 0200
Fax: 617 491 7903

News Articles [390 Associated News Articles listed on BioPortfolio]

STAT Plus: Personalized cancer therapies show great promise. The hitch? Manufacturing them efficiently

Experimental CAR-T therapies work well in blood cancers. The challenge for startups: Cranking out the personalized therapies at scale for patients worldwide.

How do we achieve optimal sequencing of therapies in CLL?

Dr Ysebaert speaks at the 'Defining treatment strategies for CLL & FL in the era of targeted therapies' symposium at EHA 2017 about achieving optimal sequencing of therapies in CLL. He also discusses...

Combining immune-based therapies with TKIs in melanomas

Prof Robert speaks with ecancer at WIN 2017 about tackling class-associated toxicity and drug resistance with combination therapies based on tyrosine kinase inhibition. Intralesional oncolytic the...

A Look at Antibody Therapies

Since we were just talking about antibody therapies in immuno-oncology, here’s a timely column by Bruce Booth at LifeSciVC on antibody therapies in general. It’s well worth a read if, like...

Chimeric antigen receptor T-cell therapies for lymphoma

Cell-based immunotherapies are showing great promise in the treatment of even the most treatment-refractory of haematological malignancies. Herein, Jennifer Brudno and James Kochenderfer review the re...

Intralesional T-VEC and combinations

Prof Agarwala speaks with ecancer at EADO 2017 about intralesional therapies, including oncolytic talimogene laherparepvec (T-VEC), to treat melanoma. He highlights the complementary roles of int...

Intralesional T-VEC and combinations for melanoma

Prof Agarwala speaks with ecancer at EADO 2017 about intralesional therapies, including oncolytic talimogene laherparepvec (T-VEC), to treat melanoma. He highlights the complementary roles of intra...

Aegis Therapies Hires New CFO to Help Lead Company Through Next Growth Phase

Plano, TX (PRWEB) September 18, 2017 Aegis Therapies, a national leader in rehabilitation and wellness services has recently expande...

PubMed Articles [745 Associated PubMed Articles listed on BioPortfolio]

Mind-Body Therapies in Cancer: What Is the Latest Evidence?

Many people living with cancer use complementary therapies, and some of the most popular are mind-body therapies (MBTs), including relaxation and imagery, hypnosis, yoga, meditation, tai chi and qigon...

Autism and Mind-Body Therapies: A Systematic Review.

Mind-body therapies are often used by people with autism spectrum disorders (ASD). However, there has been little examination into which types of mind-body therapies have been investigated for people ...

"Monoclonal antibodies in the treatment of MS: emergence of B-cell targeted therapies".

Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common causes of disability in young adults. Over the last decade, new disease modifying therapies have rapidl...

Meaningful endpoints for therapies approved for hematologic malignancies.

Overall survival (OS) is considered the gold standard for determining treatment efficacy in oncology trials, but the relation between treatment and OS can be challenging to assess because of long stud...

Palliative Therapies for Congenital Heart Disease with Ductus Dependent Pulmonary Circulation.

In neonates, the management of ductus dependent pulmonary circulation is challenging. There have been three palliative therapies for this lesion: the modified Blalock-Taussig shunt, ductal stenting an...

Clinical Trials [1310 Associated Clinical Trials listed on BioPortfolio]

Effect of Complementary and Alternative Medicine on Pain Among Inpatients

The proposed study has 3 aims: 1) quantitatively describe a model for delivering complementary and alternative medicine (CAM) therapies to understand the selection of patients and CAM ther...

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)

The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for wh...

Dysphagia After Different Swallowing Therapies

Dysphagia after stroke is associated to increased pulmonary complications and mortality. The swallowing therapies could decrease the pulmonary complications and improve the quality of life...

Outcome Analysis of POEM and Endoluminal Therapies

Evaluation of current and newly developed endoluminal therapies in the management of Upper and Lower GI conditions.

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.

Companies [821 Associated Companies listed on BioPortfolio]

Transkaryotic Therapies Incorporated RKT

Founded in 1988, Transkaryotic Therapies, Inc. (TKT) is a leading biopharmaceutical company in the production and delivery of protein therapies. TKT develops, and intends to commercialize, protein pro...


PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...


Founded in 2008 by the Axis Biotec Brasil™ group (, PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....


COOK SIS is sold under various brand names to treat a wide range of conditions including management of dermal wounds and burns, reinforcement of many types of weakened tissue, and treatment of urinary...

Toler RX Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tole...

More Information about "Transkaryotic Therapies Incorporated RKT" on BioPortfolio

We have published hundreds of Transkaryotic Therapies Incorporated RKT news stories on BioPortfolio along with dozens of Transkaryotic Therapies Incorporated RKT Clinical Trials and PubMed Articles about Transkaryotic Therapies Incorporated RKT for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Transkaryotic Therapies Incorporated RKT Companies in our database. You can also find out about relevant Transkaryotic Therapies Incorporated RKT Drugs and Medications on this site too.

Quick Search

Relevant Topic

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record